Lire la version française
BOUCHERVILLE, Quebec, Dec. 2, 2015 (GLOBE NEWSWIRE) -- Sandoz Canada is pleased to announce the launch of T/CLorazepam Injection USP 2 mg/mL, a new concentration now available in addition to its T/CLorazepam Injection USP 4 mg/mL. Lorazepam Injection USP (lorazepam) is indicated in adults for short-term relief of severe anxiety in patients with anxiety disorders, to relieve excessive anxiety before surgical procedures and to help control severe seizures (status epilepticus).
The introduction of this new product demonstrates again that Sandoz Canada is committed to maintaining its status as a trusted partner in the world of health care.
"We make every effort to meet the needs of patients and healthcare professionals while reaching the highest standards in terms of quality, compliance and service, in order to offer products at more affordable costs," said Michel Robidoux, President and General Manager at Sandoz Canada.
The foregoing release may contain forward-looking statements that can be identified by terminology such as "new", "the first" and "pioneer", or similar expressions, or by express or implied discussions regarding future sales of the above-mentioned products. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results with the above-mentioned products to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that the above-mentioned products will receive any additional marketing approvals in any other countries, or that it will reach any particular sales levels. In particular, management's expectations regarding commercialization of the above-mentioned products could be affected by, among other things, additional analysis of clinical data in respect of the above-mentioned products, new clinical data, unexpected clinical trial results, unexpected regulatory actions or delays or government regulation generally, the company's ability to obtain or maintain patent or other proprietary intellectual property protection, competition in general, increased government, industry, and general public pricing pressures, and other risks and factors referred to in the Form 20-F filed by Novartis with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sandoz is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Sandoz Canada
Established in Boucherville, Quebec, Sandoz Canada is part of Sandoz International GmbH, the world's second largest producer of generic drugs and a company of the Swiss multinational corporation, Novartis. A leader in its field, Sandoz Canada develops, produces, markets and distributes a wide range of generic products used, among others, in anesthesia, infectious diseases, oncology, dermatology, cardiology, and pain management. The Boucherville manufacturing plant specializes in the production of key injectable products.
Sandoz, a division of Novartis, is a global leader in generic pharmaceuticals, driving sustainable access to high-quality healthcare. Sandoz employs more than 26,000 people worldwide and supplies a broad range of affordable, primarily off-patent products to patients and customers around the globe.
The Sandoz global portfolio comprises approximately 1,100 molecules, which accounted for 2014 sales of USD 9.6 billion. Sandoz holds the global #1 position in biosimilars as well as in generic anti-infectives, ophthalmics and transplantation medicines.
Nearly half of Sandoz's portfolio is in differentiated products – products that are scientifically more difficult to develop and manufacture than standard generics.
In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003, Sandoz has consistently driven growth in selected geographies and differentiated product areas through a series of targeted acquisitions.
Sandoz is on Twitter. Sign up to follow @Sandoz_global at http://twitter.com/Sandoz_Global.
Photos accompanying this release are available at:
CONTACT:For further information, contact: Sandoz Canada Annick Lambert +1 450 641 4903 ext. 2964 email@example.com Sandoz Global Communications Chris Lewis +49 8024 476 1906 firstname.lastname@example.org